Loading patent…
AssigneeKeros Therapeutics, Inc.
InventorsJasbir S. SEEHRA, Jennifer LACHEY, Claire TSENG, Jason O'NEILL, Henning THØGERSEN, Elissa FURUTANI
Estimating the term…
The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.
A method of increasing lean mass or muscle mass in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an extracellular activin receptor type II (ActRII) chimera, the chimera having a sequence of any one of
A method of treating a subject having or at risk of developing a disease or condition involving weakness or atrophy of muscles, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an extracellular ActRII chimera, the chimera having a sequence of any one of
A method of treating a subject having or at risk of developing a neuromuscular disease, sarcopenia, cachexia, disuse atrophy, treatment-related muscle loss or atrophy, hypotonia, muscle loss or atrophy associated with hypoxia, or muscle loss or atrophy associated with a burn injury, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an extracellular ActRII chimera, the chimera having a sequence of any one of
Dependencies are inferred from the claim text.